Optimization of Drug Anchor for Ortho-Carborane in Reconstitution of Low Density Lipoproteins for Neutron Capture Therapy

  • Michael D. Smith
  • Yohanes Setiawan
  • Douglas E. Moore


Low density lipoproteins (LDL) have considerable potential as carriers for site-specific drug delivery.1 The core of native LDL is composed mainly of cholesteryl esters of long chain unsaturated fatty acids, which can be removed and replaced with other hydrophobic compounds. These core compounds can be regarded as specific combinations of structural units that not only provide efficient packing in the core environment, but also enhance passage through the phospholipid coat into the core. For example, it has been demonstrated that esters of unsaturated fatty acids are incorporated into heptane-extracted LDL far more effectively than esters of the corresponding saturated fatty acids.2 The aim of the present study, which is an extension of the pioneering work of Kahl et a1,3–7 is to find which combination of these structural elements forms the best drug anchor for delivery of o-carborane to a tumour in reconstituted LDL.


Cholesteryl Ester Boron Compound Cholesteryl Oleate Chain Unsaturated Fatty Acid Idaho National Engineer Laboratory 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    P. C. de Smidt & Th. J. C. van Berkel, LDL-Mediated drug targeting, Critical Reviews in Therapeutic Drug Carrier Systems, 7: 99–120, 1990.PubMedGoogle Scholar
  2. 2.
    M. Krieger, M. J. McPhaul, J. L. Goldstein, M. S. Brown, Replacement of neutral lipids of low density lipoprotein with esters of long chain unsaturated fatty acids, J. Biol. Chem., 254: 3845–3853, 1979.PubMedGoogle Scholar
  3. 3.
    Stephen B. Kahl, Tumor-specific targeting of third generation boron compounds: recent experience with porphyrins, low density lipoproteins and amino acids, in: “Boron Compounds suitable for NCT for the treatment of Cancer”, National Cancer Institute, Bethesda, MD, 1988.Google Scholar
  4. 4.
    S. B. Kahl, J. C. Callaway, New tumor localizers: advances in the use of low density lipoproteins (LDL), StrahlentherOnkol., 165: 137–139, 1989.Google Scholar
  5. 5.
    S. B. Kahl, D. Pate, B. H. Laster, E. A. Popenoe, R. G. Fairchild, In vitro biological efficacy of boronated low density lipoproteins for NCT, in: “Progress in Neutron Capture Therapy for Cancer”, Ed. B. J. Allen, D.E. Moore and B.V. Harrington, Plenum Press, New York, 1992, pp 365–368.CrossRefGoogle Scholar
  6. 6.
    S.B. Kahl and D. W. Pate, Low density lipoprotein reconstitutions with alkyl and aryl carboranes, in: “Advances in Neutron Capture Therapy”, Ed. A.H. Soloway, R.F. Barth and D.E. Carpenter, Plenum Press, New York, 1993, pp 399–402.CrossRefGoogle Scholar
  7. 7.
    S. Kahl, Reconstitution of low density lipoproteins with carborane compounds, in: INEL BNCT Research Program Annual Report 1992, Idaho National Engineering Laboratory, Idaho Falls, Idaho, 1993, pp 5–11.Google Scholar
  8. 8.
    R. J. Deckelbaum, G. G. Shipley, D. M. Small, Structure and interactions of lipids in human plasma low density lipoproteins, J. Biol. Chem., 252: 744–754, 1977.PubMedGoogle Scholar
  9. 9.
    R. N. Grimes, “Carboranes”, Academic Press, New York, 1970.Google Scholar
  10. 10.
    M. M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochern., 72: 248–254, 1976.CrossRefGoogle Scholar
  11. 11.
    Y. Setiawan, M. D. Smith, D.E. Moore, B. J. Allen, Pharmacokinetics and neutron capture therapy of melanoma xenografts using boronated low density lipoprotein. (these proceedings) Google Scholar
  12. 12.
    Y. Setiawan, T. Rise, D. E. Moore, Fourier transform infrared (FTIR) spectrometry for the assay of polyhedral boron compounds in plasma and pharmaceutical formulations, Pharm. Res., 11: 723–727, 1994.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Michael D. Smith
    • 1
  • Yohanes Setiawan
    • 1
  • Douglas E. Moore
    • 1
  1. 1.Department of PharmacyUniversity of SydneyAustralia

Personalised recommendations